Securing $12 Million in MedTech: Funding Strategies for Deep Tech Startups

Welcome back to the blog companion for our ongoing podcast series exploring the cutting edge of healthcare innovation. If you are a founder, researcher, or investor in the medical device sector, you already know that the journey from a benchtop concept to a patient-ready product is fraught with unique financial and regulatory hurdles. Raising capital for deep tech and MedTech startups is radically different from raising capital for software-as-a-service or consumer internet companies. Hardware is hard, but medical hardware is an entirely different stratosphere of complexity, long timelines, and capital intensity.

In our latest podcast episode, we sat down with Dr. Benjamin Holmes, Chief Executive Officer and Co-Founder of Nanochon, to discuss how his team successfully navigated this treacherous landscape. Nanochon has raised nearly $12 million to develop its flagship innovation, a revolutionary 3D-printed synthetic implant designed to repair damaged joint cartilage. If you want to dive deeper into Dr. Holmes's personal journey, his background in biomedical engineering, and the granular details of their technological roadmap, make sure to listen to the full conversation on Benjamin Holmes, Chief Executive Officer at Nanochon. In this post, we are going to expand on the core themes of that discussion, focusing specifically on the funding strategies, scientific hurdles, and strategic milestones that enabled Nanochon to secure vital capital and advance toward first-in-human clinical trials.

Introduction to Nanochon and the Future of Joint Repair

To understand Nanochon's financial trajectory, we first need to understand the profound clinical need they are addressing. Joint pain, specifically knee degeneration, affects millions of people worldwide. For younger, active patients who suffer from cartilage defects due to sports injuries or trauma, the clinical options are often severely limited. They are typically too young for a total knee replacement, yet standard microfracture procedures or biological repairs often fail to restore full, long-term joint function.

Enter Nanochon and their proprietary technology, Chondrograft. Founded in 2016, Nanochon set out to bridge this massive gap in orthopedic care. By developing a synthetic, 3D-printed implant that mimics the mechanical and biological properties of real cartilage and bone, the company aims to give patients their mobility back without forcing them to undergo invasive, life-altering joint replacements prematurely. However, building a novel orthopedic implant requires extensive research, rigorous preclinical testing, and significant capital long before a single dollar of revenue can be generated. For Nanochon, the challenge was clear: how do you convince investors to fund a hardware-heavy, long-horizon medical device company in its earliest stages?

The Science Behind 3D-Printed Orthopedic Implants

Before investors write checks, especially in deep tech, they need to understand the core technology and verify that it solves a genuine market problem better than existing alternatives. Dr. Benjamin Holmes brought a deep technical foundation to Nanochon, holding a Ph.D. in Biomedical Engineering from The George Washington University and a B.S. in Mechanical and Aerospace Engineering from the University of Virginia. This engineering pedigree directly influenced the development of Nanochon's proprietary manufacturing and material science approaches.

Cartilage is notoriously difficult to repair because it lacks a direct blood supply, meaning it does not heal easily on its own. Nanochon tackled this problem by leveraging advanced 3D printing and specialized biomaterials. The Chondrograft implant is engineered to have a dual-zone structure: a porous lower section that encourages native bone ingrowth and a smooth upper surface designed to mimic articular cartilage. This complex architecture requires precise manufacturing controls, material biocompatibility, and structural integrity that can withstand the immense mechanical loads placed on human joints.

For entrepreneurs looking to raise capital, Nanochon's approach highlights a fundamental rule of deep tech fundraising: your science must be defensible. Patents, proprietary manufacturing methods, and clear peer-reviewed data serve as the bedrock of investor confidence. When venture capitalists and grant reviewers look at an early-stage MedTech company, they are evaluating risk. Demonstrating a deep mastery of the underlying material science and manufacturing processes is the fastest way to mitigate perceived technical risk.

Navigating the MedTech Funding Landscape

The financial ecosystem for medical technology is distinct from almost every other venture capital sector. Traditional software startups can often launch a minimum viable product with minimal capital, iterate rapidly based on user feedback, and achieve profitability or venture-scale growth within a few years. MedTech startups, conversely, face a long valley of death characterized by expensive regulatory pathways, rigorous biocompatibility testing, and protracted clinical trials.

Because of this high-risk, high-capital reality, relying solely on traditional venture capital from day one is often impossible or highly dilutive. Early-stage MedTech founders must assemble a diversified capital stack. This stack typically combines non-dilutive funding sources—such as government grants, academic partnerships, and pitch competition prizes—with strategic angel investors and specialized venture capital firms that understand the healthcare sector.

Nanochon’s masterclass in fundraising involved blending these different capital sources strategically over time. By utilizing non-dilutive funding to de-risk the technology in its infancy, Nanochon preserved precious equity for the founders and early employees while building the foundational data required to attract institutional venture capital down the road.

Leveraging Non-Dilutive Funding Through NSF Grants

One of the most powerful and underutilized resources for deep tech and MedTech startups in the United States is the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program, often referred to as America's Seed Fund. These programs are backed by federal agencies like the National Science Foundation (NSF), the National Institutes of Health (NIH), and the Department of Defense.

Dr. Holmes and the Nanochon team successfully leveraged NSF grants to fund the early, high-risk R&D phases of their 3D-printed implant technology. Non-dilutive funding is essentially free money; the government does not take an equity stake in your company in exchange for the grant funds. For a pre-revenue medical device startup, this is a game-changer.

However, winning an NSF or NIH grant is far from easy. It requires rigorous scientific proposals, clear commercialization plans, and a deep understanding of what federal reviewers are looking for. To successfully secure non-dilutive funding, founders must:

1. Align with National Priorities

Federal agencies fund projects that promise significant public benefit. In Nanochon's case, addressing the debilitating impacts of joint degeneration and reducing the societal burden of joint replacements aligned perfectly with healthcare innovation priorities.

2. Build Strong Academic Partnerships

Many grants look favorably on collaborations between early-stage startups and academic research institutions, leveraging existing laboratory infrastructure and academic expertise.

3. Demonstrate a Clear Path to Commercialization

Even though grants focus heavily on research and development, agencies want to ensure that the technology will eventually transition out of the lab and into the real world to help patients.

Transitioning from Venture Capital to First-in-Human Clinical Trials

While non-dilutive grants are vital for getting a MedTech startup off the ground, there comes a point in every hardware company's lifecycle where institutional capital is required to scale operations, build manufacturing lines, and execute clinical trials. Clinical trials are the ultimate proving ground for any medical device, and they are notoriously expensive.

Nanochon successfully bridged the gap from grant funding to venture capital, ultimately securing nearly $12 million in total funding. This influx of capital enabled the company to transition from preclinical benchtop testing and animal studies to the ultimate milestone for any medical device company: first-in-human clinical trials.

Moving into human trials changes the risk profile of a startup entirely. Investors who were previously hesitant due to regulatory uncertainty suddenly see a clear, tangible path toward market clearance and commercial revenue. However, managing this transition requires meticulous planning, stringent regulatory compliance with bodies like the FDA, and operational excellence to ensure patient safety and data integrity.

Key Takeaways for Deep Tech and MedTech Entrepreneurs

The journey of Nanochon offers a blueprint for aspiring medical device entrepreneurs and deep tech founders navigating the complex world of startup capital. Here are the core lessons to keep in mind:

1. Master Your Capital Stack

Do not rely on a single funding source. Combine non-dilutive government grants, angel investments, and specialized venture capital to minimize equity dilution while maintaining the financial runway necessary to achieve major milestones.

2. De-Risk the Science Early

Investors want to back technology that works. Use grant funding and academic collaborations to validate your material science, manufacturing processes, and preclinical efficacy before pitching institutional VCs.

3. Keep Your Eyes on the Clinical Horizon

Every decision you make in a MedTech startup—from engineering design to fundraising strategy—should ultimately serve the goal of safely delivering a life-changing product to patients in a clinical setting.

To hear the full, inspiring conversation with Dr. Benjamin Holmes and learn more about how Nanochon is shaping the future of orthopedic care, be sure to listen to our complete podcast episode. You can stream the full interview and access additional resources directly by visiting Benjamin Holmes, Chief Executive Officer at Nanochon. Stay tuned for more deep dives into the innovators and breakthroughs transforming global clinical trials and healthcare technology!